EXACTA · UNITED STATES
LIQUID IMPACT pilot study
Patil D and colleagues • Frontiers in Oncology • 2022
- DOI
- 10.3389/fonc.2022.972322
- Design
- Single-arm pilot of treatment informed by multi-analyte liquid biopsy; preceded by a separate feasibility analysis.
- Population
- 29 in the intent-to-treat cohort; 26 evaluable. Feasibility cohort: 1,299 cases.
- Endpoints
- Objective response, disease control, progression-free survival, and overall survival.
- Reported results
- 12/26 evaluable patients had a partial response (46.2%); median progression-free survival was 4.3 months and overall survival 8.8 months.
- Limitations
- Small pilot with no randomized comparator. The 1,299-case feasibility cohort is not the treatment-outcome cohort.
- Funding and conflicts
- Funded by Datar Cancer Genetics. Multiple authors were sponsor employees; one was the founder.